Press release
Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference
--Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE® (amikacin liposome inhalation suspension) to be
About this update from Insmed Incorporated
[{"type":"text","content":"--Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE® (amikacin liposome inhalation suspension) to be Presented in Poster Discussion Session--\n--Analysis of Phase 2 WILLOW Study Evaluating the Benefit-Risk Profile of Brensocatib in Adult Patients with Non-Cystic Fibrosis Bronchiectasis to be Presented in Mini-Symposium--\nBRIDGEWATER, N.J., March 28, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that seven posters across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be presented at the American Thoracic Society (ATS) 2022 International Conference, taking place May 13-18, 2022, in San Francisco.\n\"ATS provides us with the opportunity to present the first real-world data on adding ARIKAYCE to the standard treatment regimen for patients living with refractory MAC lung disease,\" said Martina Flammer, M.D., M.B.A, Chief Medical Officer of Insmed. \"This year's conference will also highlight Insmed's growing pipeline of potential therapies for individuals living with serious and rare diseases. The wide range of data presentations reflects our steadfast commitment to scientific advancement that has the potential to make a significant impact on patients' lives.\"\nPresentations include:\nThematic poster session, Sunday, May 15, 11:15 AM-1:15 PM PT: A1945/P250 – Treprostinil Exerts Anti-Fibrotic Effects via the Prostanoid Receptor Subtype EP2 in Human Lung FibroblastThematic poster session, Sunday, May 15, 11:15 AM-1:15 PM PT: A1471/P670 – Pulmonary Exacerbations (PEx) and Hospitalizations in Commercially Insured Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) Over 1- and 2-Year Follow-Up PeriodsPoster discussion session, Tuesday, May 17, 9:30-11:00 AM PT: A3866/302 – Reduction in Hospitalizations Following Initiation of Amikacin Liposome Inhalation Suspension: A Retrospective Cohort Study of Patients in Real-world SettingsPoster discussion session, Tuesday, May 17, 9:30-11:00 AM PT: A3879/315 – The Hospitalization Burden Among Treatment-refractory Nontuberculous Mycobacterial Lung Disease Patients in JapanThematic poster session, Tuesday, May 17, 11:15 AM-1:15 PM PT: A4613/P1002 –Admi...